Abstract: The invention relates to a neovascularization inhibitor composition comprising a compound of the following general formula ?I! or a salt thereof, or a solvate thereof, as an active ingredient, ##STR1## wherein R.sup.1 represents hydrogen, optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; R.sup.2 represents optionally substituted alkyl, aralkyl, arylalkenyl, or aryl; or R.sup.1 and R.sup.2 conjoinedly and taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group optionally containing nitrogen, oxygen, or sulfur as a ring member in addition to said N atom and optionally being further substituted.

Abstract: The invention relates to a medicinal composition comprising a triazine derivative of the following general formula ?I! ##STR1## or a solvate thereof, or a salt thereof, as an active ingredient. In the above formula, R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, unsubstituted or substituted alkyl aralkyl, or alkenyl, or jointly represent cyclic amino (NR.sup.1 R.sup.2) in combination with the adjacent nitrogen atom. The cyclic amino may contain nitrogen, oxygen, or sulfur as a ring member in addition to the adjacent nitrogen and may be further substituted. Excluded is the case in which NR.sup.1 R.sup.2 is NH.sub.2. The compound of the invention is useful as a therapeutic drug for hepatitis.

Abstract: The invention relates to a therapeutic drug for pancreatitis which comprises a compound of the following general formula ?I! or a salt thereof, or a solvate thereof. ##STR1## In the above formula, R.sup.1 and R.sup.2 may be the same or different and each represents hydrogen, alkyl which may be substituted, aralkyl, arylalkenyl, or aryl, or R.sup.1 and R.sup.2 taken together with the adjacent N atom, i.e. in the form of NR.sup.1 R.sup.2, represent a 4- through 8-membered cyclic amino group, which cyclic amino group may contain nitrogen, oxygen, or sulfur as a ring member in addition to the above-mentioned N atom and may be further substituted.

Abstract: Compounds of the formula I ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1 is hydrogen, lower alkyl, aryl or haloaryl, in combination with a pharmaceutically acceptable carrier.

Abstract: Compounds of the formula I ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1 is hydrogen or lower alkyl and R.sup.2 and R.sup.3 are the same or different and each is hydrogen, lower alkoxy or halo, in combination with a pharmaceutically acceptable carrier have been found to be useful as nootropic agents.

Abstract: Benzimidazole derivatives of the formula (I): ##STR1## or a pharmaceutically acceptable acid addition salt thereof wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is ##STR2## or --C.tbd.C--Ar wherein Ar is phenyl unsubstituted or substituted by one to three substituents selected from the group consisting of halo, lower alkyl, hydroxy, unsubstituted or substituted lower alkoxy, aralkyloxy wherein the alkyl moiety is a lower alkyl moiety, lower alkenyloxy, lower alkynyloxy, difluoromethoxy, lower alkylamino, methylenedioxy, trifluoromethyl, cyano, lower alkylthio and lower alkylsulfinyl; R.sup.4, R.sup.5, R.sup.6 and R.sup.7 a hydrogen or lower alkyl or R.sup.4 and R.sup.5 together with the carbon atoms to which they are attached form a cyclopropyl ring; and R.sup.3 is hydrogen, lower alkyl, acyl or lower alkylsulphonyl are useful in the treatment of ulcers of the stomach and duodenum in humans and animals.

Abstract: 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine and pharmaceutically acceptable acid addition salts thereof in finely pulverized form so that the average particle diameter is 20 microns or less have been found to be particularly useful for the treatment of peptic ulcers. When administered to humans in need thereof, 1 to 4 mg per day has been found effective.

Abstract: 2,4-Diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine and pharmaceutically acceptable acid addition salts thereof in finely pulverized form so that the average particle diameter is 20 microns or less have been found to be particularly useful for the treatment of peptic ulcers.

Abstract: A method of prevention and/or treatment of disorders of the liver, kidney, colon or rectum in mammals including humans which comprises administering to the patient a therapeutically effective amount of 2,4-diamino-6-(2',5-dichlorophenyl)-s-triazine maleate sufficient to prevent and/or overcome said disorders, and pharmaceutical compositions therefor.

Abstract: 2,4-Diamino-6-phenyl-s-triazine derivatives which are substituted in the 3-position of the phenyl ring and optionally further substituted in the 6-position demonstrate anti-ulcer and diuretic properties. A representative embodiment is 2,4-diamino-6-(3-trifluoromethylthiophenyl)-s-triazine.

Abstract: The mono-, bis- and trisnicotinoyl derivatives of melamine and the corresponding mono- and bisnicotinoyl derivatives of benzoguanamine demonstrate anti-ulcer and diuretic activity. A representative embodiment is 2-nicotinamido-4,6-diamino-s-triazine.

Abstract: A series of novel benzoguanamine derivatives possessing a high anti-peptic ulcer activity with low toxicity has been prepared by the reaction of the corresponding dihalogenobenzonitriles with dicyandiamide or by the reaction of the corresponding carboxylic acids or functional derivatives thereof with biguanide.